An observational study in Patient With an Appointment for an Abdominal CT Scan and Able to Stand up for Height Measurement, sponsored by University Hospital, Grenoble. Not yet recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.
Sponsored by University Hospital, Grenoble · Observational
The TAILLE study is a single-center, non-interventional (RIPH3), uncontrolled, non-randomized, open-label study.prospective study conducted at CHU Grenoble Alpes.
The goal is to evaluate the reliability of an AI algorithm developed as part of the TAILLE-pilot study to estimate height from abdominal CT scan data and relevant clinical data like age and gender.
The TAILLE-pilot study , is a pilot data study (RNIPH) aimed at developing artificial intelligence algorithms using a retrospective cohort, developed by our team. It is based on AI algorithms trained to predict height from abdominal CT scan volumes.
The TAILLE study therefore aims to prospectively evaluate the performance of this algorithm in a new cohort of adult patients scheduled for an abdominal CT scan. We hypothesize that height can be reliably estimated using this algorithm, potentially with greater accuracy at the individual level than self-reported height, the limitations of which have been documented in the literature.
As part of the TAILLE study, we will compare three methods of height estimation or measurement :
The TAILLE study aims to prospectively validate the AI-algorithm, hypothesizing that it provides a more reliable estimate of height than self-reported height.
1,208 studies on the registry are indexed under Sarcopenia; 402 are open to participants now.
This study's planned enrollment of 200 is above the median of 120 across 419 observational studies indexed under Sarcopenia.
Browse Sarcopenia studies →University Hospital, Grenoble is the lead sponsor of 816 studies on the registry; 206 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patient with a scheduled appointment for an abdominal CT scan in the Radiology Department of CHUGA
Exclusion Criteria:
Height and weight measured and collection of patient self-reported height and weight
Assessment of the reliability of an AI algorithm developed as part of the TAILLE-pilot study to estimate height from abdominal CT scan and relevant clinical data, such as gender and sex
Assessment of the differences between CRA-measured height and AI-estimated height (CRA = Clinical Research Associate). CRA-measured height is the reference
Time frame: At enrollement
Assessment the most reliable method for height estimation by comparing self-reported and AI-estimated height with CRA-measured height
Differences between CRA-measured height and self-reported height, and between CRA-measured height and AI-estimated height
Time frame: At enrollment
Identification of factors that may influence the reliability of the AI algorithm for height estimation, particularly gender and age
Difference between CRA-measured height and AI-estimated height according to factors that may affect the reliability of the algorithm, particularly gender and age
Time frame: At enrollment
Assessment of the impact of using self-reported height and AI-estimated height on sarcopenia risk classification
In a hypothetical clinical context, change in sarcopenia risk category according to the SMI value calculated from the muscle area determined by the ODIASP software. Sarcopenia risk will be defined according to the thresholds established by the French National Authority for Health (HAS): men, SMI \< 52.4 cm²/m²; women, SMI \< 38.5 cm²/m²
Time frame: At enrollment
Assessment of the impact of using self-reported height and AI-estimated height on the calculation of the theoretical chemotherapy dose
In a hypothetical clinical context, percentage of patients receiving a chemotherapy dose lower than 85% of the theoretical dose, a threshold below which impaired prognosis has been reported (Nielson et al., 2021). The dose will be calculated based on body surface area, which depends on the weight measured by the CRA and height. The analyses will focus in particular on commonly used chemotherapy regimens for gastrointestinal cancers: 5-fluorouracil 2,400 mg/m², gemcitabine 1,000 mg/m², and oxaliplatin 85 mg/m²
Time frame: At enrollment
Assessment of the impact of using self-reported height and AI-estimated height on chronic kidney disease (CKD) staging estimated using the CKD-EPI equation adjusted for body surface area
In a hypothetical clinical context, change in CKD stage determined based on the estimated glomerular filtration rate calculated using the CKD-EPI equation adjusted for body surface area, using the same methodology as for CJS4. This endpoint will be analyzed provided that a serum creatinine value is available in the medical record
Time frame: At enrollment
Plan to share: Undecided
No publications or documents are linked to this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Grenoble